Collaboration will identify molecules that interfere with pathways controlling cell fate specification.

Debiopharm  and Ecole Polytechnique Federale de Lausanne are working together to identify small molecules and peptides that interfere with pathways controlling cell-fate specification.

“Targeting pathways controlling cell-fate specification could generate innovative anticancer drugs with antitumoral, antimetastatic, and antiangiogenic properties to treat tumors that are currently resistant to standard therapies,” says Kamel Besseghir, CEO of Debiopharm.

The project will be called Debio 0826. Freddy Radtke, Ph.D., associate professor at the Swiss Institute for Experimental Cancer Research (ISREC) and Gerardo Turcatti, Ph.D., MER, director of the Biomolecular Screening Facility (BSF) will lead the research.

Previous articleAdolor Recovers Rights from GSK to Entereg® for OBD
Next articleProteins Linked to HIV-Resistance Identified in Kenyan Sex Workers